Volume 18 Issue 8, August 2019

Volume 18 Issue 8

'Bispecific antibodies,' inspired by the Review on p585.

Cover design: Susanne Harris.

Comment

  • Comment |

    The Biomarkers Consortium aims to facilitate drug development with biomarkers across a range of diseases. Here, we briefly highlight its accomplishments so far and its recent expansion in scope to include related tools along the lines of the Biomarkers, EndpointS and other Tools (BEST) resource, such as patient-reported outcomes and clinical outcome assessments.

    • Joseph P. Menetski
    • , Christopher P. Austin
    • , Linda S. Brady
    • , Guy Eakin
    • , Chris Leptak
    • , Abbey Meltzer
    •  & John A. Wagner

News & Analysis

  • News |

    Small-molecule drugs and biologics that alter the microbiome or its interaction with host tissues are poised to change the face of microbiome therapeutics.

    • Megan Cully
  • News in Brief

  • Biobusiness Briefs

  • An Audience With

  • An Audience With |

    Daphne Koller didn’t anticipate becoming a drug hunter when she joined Stanford University as a professor of machine learning in 1995. But after stumbling into biology a few years later because of the novelty of the small but diverse data sets it offered, the field quickly drew her in. By 2016, she was the chief computing officer at Alphabet’s ageing-focused biotech Calico. She then founded the biotech insitro in 2018 to explicitly generate high-quality biological data sets at high throughput to enable the application of machine learning to drug discovery. She spoke with Asher Mullard about her vision for machine learning in drug discovery, the need to view data as a core asset of a business rather than a byproduct and how to foster computational excellence in biopharma.

    • Asher Mullard
  • From the Analyst's Couch

Research Highlights

Reviews

  • Review Article |

    Bispecific antibodies — a large family of molecules that are designed to recognize two different epitopes or antigens — come in many formats and can have the potential for novel functionalities that are not provided by mixtures of monoclonal antibodies. This article reviews the current bispecific antibody landscape from a mechanistic perspective, including a comprehensive overview of the pipeline.

    • Aran F. Labrijn
    • , Maarten L. Janmaat
    • , Janice M. Reichert
    •  & Paul W. H. I. Parren
  • Review Article |

    Bromodomains are attractive targets from a chemical and structural perspective. The promising therapeutic effects of BET bromodomain inhibitors prompted chemical probe development to understand the potential of new agents targeting bromodomains. This Review discusses the next wave of bromodomain inhibitors with clinical potential in oncology and non-oncology indications.

    • Andrea G. Cochran
    • , Andrew R. Conery
    •  & Robert J. Sims III
  • Review Article |

    Aminoacyl-tRNA synthetases (ARSs) are essential enzymes for protein synthesis with evolutionarily conserved enzymatic mechanisms. Research advances have unveiled unexpected disease-associated alterations in human ARSs that have highlighted their potential as therapeutic targets. This Review addresses the emerging biology and therapeutic applications of human ARSs.

    • Nam Hoon Kwon
    • , Paul L. Fox
    •  & Sunghoon Kim